Darolutamide Increases Survival in Metastatic Hormone-Sensitive Prostate Cancer

BREAKING NEWS 2022

 New research suggests that adding darolutamide to androgen deprivation therapy (ADT) and docetaxel improves overall survival for patients with metastatic hormone-sensitive prostate cancer (mHSPC), compared with ADT plus docetaxel alone.

In addition, darolutamide significantly delayed the development of castration-resistant prostate cancer (CRPC) and time to pain progression.

These findings from the phase 3 ARASENS trial were presented at the ASCO Genitourinary Cancers Symposium 2022 and published concurrently in the New England Journal of Medicine.

“Based on the results of ARASENS, we conclude that darolutamide in combination with ADT and docetaxel should become the new standard of care for the treatment of patients with mHSPC,” said Matthew R. Smith, MD, PhD, of Massachusetts General Hospital Cancer Center in Boston, when presenting the results.

Renal and Urology News, 2022, Feb 28.